{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:51:58Z","timestamp":1784011918350,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12288-024-01787-x","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T09:02:07Z","timestamp":1716022927000},"page":"60-68","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Outcomes of Pediatric Acute Lymphoblastic Leukemia in the Bajio Region of Mexico: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"41","author":[{"given":"Octavio","family":"Mart\u00ednez Villegas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma Eryca","family":"Alatoma Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Javier","family":"Romero V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Andrade Colmenero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertha Elizabeth","family":"Tirado L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"Toala Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betzayda","family":"Valdez Garibay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca Olivia","family":"Murillo Ort\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4900-4726","authenticated-orcid":false,"given":"Lauro Fabi\u00e1n","family":"Amador Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"issue":"3","key":"1787_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"1787_CR2","unstructured":"National Cancer Institute. NCCR*Explorer: An interactive website for NCCR cancer statistic. Retrieved from https:\/\/NCCRExplorer.ccdi.cancer.gov.\u00a0Accessed 15 Mar 2024"},{"issue":"14","key":"1787_CR3","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1186\/1471-2407-14-790","volume":"29","author":"R Rivera-Luna","year":"2014","unstructured":"Rivera-Luna R, Shalkow-Klincovstein J, Velasco-Hidalgo L et al (2014) Descriptive Epidemiology in Mexican children with cancer under an open national public health insurance program. BMC Cancer 29(14):790. https:\/\/doi.org\/10.1186\/1471-2407-14-790","journal-title":"BMC Cancer"},{"issue":"9","key":"1787_CR4","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3390\/jcm10091926","volume":"10","author":"H Inaba","year":"2021","unstructured":"Inaba H, Pui CH (2021) Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia. J Clin Med 10(9):1926. https:\/\/doi.org\/10.3390\/jcm10091926","journal-title":"J Clin Med"},{"issue":"11","key":"1787_CR5","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031.PMID:33054110;PMCID:PMC7604619","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba H, Mullighan CG (2020) Pediatric acute lymphoblastic leukemia. Haematologica 105(11):2524\u20132539. https:\/\/doi.org\/10.3324\/haematol.2020.247031.PMID:33054110;PMCID:PMC7604619","journal-title":"Haematologica"},{"issue":"3","key":"1787_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11899-019-00515-x","volume":"14","author":"LE Winestone","year":"2019","unstructured":"Winestone LE, Aplenc R (2019) Disparities in Survival and Health Outcomes in Childhood Leukemia. Curr Hematol Malig Rep 14(3):179\u2013186. https:\/\/doi.org\/10.1007\/s11899-019-00515-x","journal-title":"Curr Hematol Malig Rep"},{"key":"1787_CR7","doi-asserted-by":"publisher","first-page":"12827","DOI":"10.1002\/cam4.5951","volume":"11","author":"M Davitt","year":"2023","unstructured":"Davitt M, Gennarini L, Loeb D, Fazzari M, Hosgood HD (2023) Impact of race\/ethnicity and language preferences on pediatric ALL survival outcomes. Cancer Med 11:12827\u201312836. https:\/\/doi.org\/10.1002\/cam4.5951","journal-title":"Cancer Med"},{"issue":"2","key":"1787_CR8","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1016\/S2352-3026(22)00371-4","volume":"10","author":"S Gupta","year":"2023","unstructured":"Gupta S, Dai Y, Chen Z et al (2023) Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children\u2019s Oncology Group cohort trials. Lancet Haematol 10(2):e129\u2013e141. https:\/\/doi.org\/10.1016\/S2352-3026(22)00371-4","journal-title":"Lancet Haematol"},{"key":"1787_CR9","doi-asserted-by":"publisher","first-page":"102275","DOI":"10.1016\/j.canep.2022.102275","volume":"81","author":"AE Janitz","year":"2022","unstructured":"Janitz AE, Barber R, Campbell JE et al (2022) Measuring disparities in event-free survival among children with acute lymphoblastic leukemia in an academic institute in Oklahoma, 2005\u20132019. Cancer Epidemiol 81:102275. https:\/\/doi.org\/10.1016\/j.canep.2022.102275","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"1787_CR10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/1043454220907547","volume":"37","author":"IJ Eche","year":"2020","unstructured":"Eche IJ, Aronowitz T (2020) A Literature Review of Racial Disparities in Overall Survival of Black Children with Acute Lymphoblastic Leukemia Compared with White Children with Acute Lymphoblastic Leukemia. J Pediatr Oncol Nurs 37(3):180\u2013194. https:\/\/doi.org\/10.1177\/1043454220907547","journal-title":"J Pediatr Oncol Nurs"},{"issue":"8","key":"1787_CR11","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.arcmed.2017.01.004","volume":"47","author":"JC Jaime-P\u00e9rez","year":"2016","unstructured":"Jaime-P\u00e9rez JC, L\u00f3pez-Razo ON, Garc\u00eda-Arellano G et al (2016) Results of Treating Childhood Acute Lymphoblastic Leukemia in a Low-middle Income Country: 10 Year Experience in Northeast Mexico. Arch Med Res 47(8):668\u2013676. https:\/\/doi.org\/10.1016\/j.arcmed.2017.01.004","journal-title":"Arch Med Res"},{"issue":"1","key":"1787_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.21149\/13210","volume":"64","author":"P Mu\u00f1oz-Aguirre","year":"2022","unstructured":"Mu\u00f1oz-Aguirre P, Zapata-Tarr\u00e9s M, Espinosa-Tamez P, S\u00e1nchez-Blas H, Brochier M, Lamadrid-Figueroa H (2022) Childhood acute lymphoblastic leukemia in Mexico: mortality trend analysis, 1998\u20132018. Salud Publica Mex 64(1):26\u201334. https:\/\/doi.org\/10.21149\/13210","journal-title":"Salud Publica Mex"},{"issue":"9596","key":"1787_CR13","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP (2007) STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X","journal-title":"Lancet"},{"issue":"20","key":"1787_CR14","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"1","key":"1787_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12288-022-01541-1","volume":"39","author":"R Chadha","year":"2023","unstructured":"Chadha R, Udayakumar DS, Sangwan S et al (2023) Cytogenetic Risk Stratification of B-Acute Lymphoblastic Leukemia and Its Correlation with Other Prognostic Factors. Indian J Hematol Blood Transfus 39(1):141\u2013145. https:\/\/doi.org\/10.1007\/s12288-022-01541-1","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"Suppl 1","key":"1787_CR16","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1007\/s00277-004-0850-2","volume":"83","author":"CH Pui","year":"2004","unstructured":"Pui CH, Relling MV, Sandlund JT, Downing JR, Campana D, Evans WE (2004) Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol 83(Suppl 1):S124\u2013S126. https:\/\/doi.org\/10.1007\/s00277-004-0850-2","journal-title":"Ann Hematol"},{"issue":"9","key":"1787_CR17","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1182\/blood-2004-04-1616","volume":"104","author":"CH Pui","year":"2004","unstructured":"Pui CH, Sandlund JT, Pei D et al (2004) Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children\u2019s Research Hospital. Blood 104(9):2690\u20132696. https:\/\/doi.org\/10.1182\/blood-2004-04-1616","journal-title":"Blood"},{"issue":"6","key":"1787_CR18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.leukres.2014.03.016","volume":"38","author":"A Koka","year":"2014","unstructured":"Koka A, Saygin C, Uzunaslan D, Ozdemir N, Apak H, Celkan T (2014) A 17-year experience with ALL-BFM protocol in acute lymphoblastic leukemia: prognostic predictors and interruptions during protocol. Leuk Res 38(6):699\u2013705. https:\/\/doi.org\/10.1016\/j.leukres.2014.03.016","journal-title":"Leuk Res"},{"issue":"12","key":"1787_CR19","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1182\/blood.2021012328","volume":"139","author":"S Buchmann","year":"2022","unstructured":"Buchmann S, Schrappe M, Baruchel A et al (2022) Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium. Blood 139(12):1785\u20131793. https:\/\/doi.org\/10.1182\/blood.2021012328","journal-title":"Blood"},{"issue":"27","key":"1787_CR20","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"CH Pui","year":"2015","unstructured":"Pui CH, Yang JJ, Hunger SP et al (2015) Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol 33(27):2938\u201348. https:\/\/doi.org\/10.1200\/JCO.2014.59.1636","journal-title":"J Clin Oncol"},{"issue":"22","key":"1787_CR21","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","volume":"34","author":"R Pieters","year":"2016","unstructured":"Pieters R, de Groot-Kruseman H, Van der Velden V et al (2016) Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol 34(22):2591\u20132601. https:\/\/doi.org\/10.1200\/JCO.2015.64.6364","journal-title":"J Clin Oncol"},{"issue":"8","key":"1787_CR22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","volume":"15","author":"A Vora","year":"2014","unstructured":"Vora A, Goulden N, Mitchell C et al (2014) Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol 15(8):809\u2013818. https:\/\/doi.org\/10.1016\/S1470-2045(14)70243-8","journal-title":"Lancet Oncol"},{"issue":"3","key":"1787_CR23","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/leu.2017.265","volume":"32","author":"N Toft","year":"2018","unstructured":"Toft N, Birgens H, Abrahamsson J et al (2018) Results of NOPHO ALL2008 treatment for patients aged 1\u201345 years with acute lymphoblastic leukemia. Leukemia 32(3):606\u2013615. https:\/\/doi.org\/10.1038\/leu.2017.265","journal-title":"Leukemia"},{"issue":"13","key":"1787_CR24","doi-asserted-by":"publisher","first-page":"1255555","DOI":"10.3389\/fonc.2023.1255555","volume":"18","author":"DC Moreira","year":"2023","unstructured":"Moreira DC, Gonz\u00e1lez-Ramella O, Echavarr\u00eda Valenzuela M et al (2023) Evaluation of factors leading to poor outcomes for pediatric acute lymphoblastic leukemia in Mexico: a multi-institutional report of 2,116 patients. Front Oncol 18(13):1255555. https:\/\/doi.org\/10.3389\/fonc.2023.1255555","journal-title":"Front Oncol"},{"issue":"13","key":"1787_CR25","doi-asserted-by":"publisher","first-page":"1254233","DOI":"10.3389\/fonc.2023.1254233","volume":"30","author":"C Duffy","year":"2023","unstructured":"Duffy C, Graetz DE, Lopez AMZ et al (2023) Retrospective analysis of outcomes for pediatric acute lymphoblastic leukemia in South American centers. Front Oncol 30(13):1254233. https:\/\/doi.org\/10.3389\/fonc.2023.1254233","journal-title":"Front Oncol"},{"issue":"1","key":"1787_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jped.2018.07.013","volume":"96","author":"S Abdelmabood","year":"2020","unstructured":"Abdelmabood S, Fouda AE, Boujettif F, Mansour A (2020) Treatment outcomes of children with acute lymphoblastic leukemia in a middle-income developing country: high mortalities, early relapses, and poor survival. J Pediatr (Rio J) 96(1):108\u2013116. https:\/\/doi.org\/10.1016\/j.jped.2018.07.013","journal-title":"J Pediatr (Rio J)"},{"issue":"Suppl 1","key":"1787_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/bloodadvances.2018GS112240","volume":"2","author":"M Ornelas-S\u00e1nchez","year":"2018","unstructured":"Ornelas-S\u00e1nchez M, Nu\u00f1o-V\u00e1zquez L, Loera-Reyna A et al (2018) The \u201cGolden Hour\u201d: a capacity-building initiative to decrease life-threating complications related to neutropenic fever in patients with hematologic malignancies in low- and middle-income countries. Blood Adv 2(Suppl 1):63\u201366. https:\/\/doi.org\/10.1182\/bloodadvances.2018GS112240","journal-title":"Blood Adv"},{"issue":"5","key":"1787_CR28","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/cncr.34572","volume":"129","author":"D Espinoza","year":"2023","unstructured":"Espinoza D, Blanco Lopez JG, Vasquez R, Fu L et al (2023) How should childhood acute lymphoblastic leukemia relapses in low-income and middle-income countries be managed: The AHOPCA-ALL study group experience. Cancer 129(5):771\u2013779. https:\/\/doi.org\/10.1002\/cncr.34572","journal-title":"Cancer"},{"issue":"9757","key":"1787_CR29","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","volume":"376","author":"C Parker","year":"2010","unstructured":"Parker C, Waters R, Leighton C et al (2010) Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 376(9757):2009\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(10)62002-8","journal-title":"Lancet"},{"issue":"11","key":"1787_CR30","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1080\/10428194.2020.1779260","volume":"61","author":"JM Shoag","year":"2020","unstructured":"Shoag JM, Barredo JC, Lossos IS, Pinheiro PS (2020) Acute lymphoblastic leukemia mortality in Hispanic Americans. Leuk Lymphoma 61(11):2674\u20132681. https:\/\/doi.org\/10.1080\/10428194.2020.1779260","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1787_CR31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/08880018.2023.2186553","volume":"40","author":"V Mishra","year":"2023","unstructured":"Mishra V, Jain S, Anand V, Malhotra P, Tejwani N, Kapoor G (2023) Impact of minimal residual disease on relapse in childhood acute lymphoblastic leukemia: Lessons learnt from a tertiary cancer center in India. Pediatr Hematol Oncol 40(6):517\u2013528. https:\/\/doi.org\/10.1080\/08880018.2023.2186553","journal-title":"Pediatr Hematol Oncol"},{"issue":"6","key":"1787_CR32","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11684-020-0759-8","volume":"14","author":"CH Pui","year":"2020","unstructured":"Pui CH (2020) Precision medicine in acute lymphoblastic leukemia. Front Med 14(6):689\u2013700. https:\/\/doi.org\/10.1007\/s11684-020-0759-8","journal-title":"Front Med"},{"issue":"1","key":"1787_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12885-022-09522-3","volume":"22","author":"LN Toksvang","year":"2022","unstructured":"Toksvang LN, Als-Nielsen B, Bacon C et al (2022) Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine\/methotrexate-based maintenance therapy in pediatric and adult patients (0\u201345 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol. BMC Cancer 22(1):483. https:\/\/doi.org\/10.1186\/s12885-022-09522-3","journal-title":"BMC Cancer"},{"issue":"35","key":"1787_CR34","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.19.01692","volume":"37","author":"S Jeha","year":"2019","unstructured":"Jeha S, Pei D, Choi J et al (2019) Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. J Clin Oncol 37(35):3377\u20133391. https:\/\/doi.org\/10.1200\/JCO.19.01692","journal-title":"J Clin Oncol"},{"issue":"2","key":"1787_CR35","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/cancers14020458","volume":"14","author":"K Pawinska-Wasikowska","year":"2022","unstructured":"Pawinska-Wasikowska K, Wieczorek A, Balwierz W, Bukowska-Strakova K, Surman M, Skoczen S (2022) Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory\/Relapsed Acute Lymphoblastic Leukemia. Cancers (Basel) 14(2):458. https:\/\/doi.org\/10.3390\/cancers14020458","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1787_CR36","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/pbc.24871","volume":"61","author":"C Pacheco","year":"2014","unstructured":"Pacheco C, Lucchini G, Valsecchi MG et al (2014) Childhood acute lymphoblastic leukemia in Nicaragua: long-term results in the context of an international cooperative program. Pediatr Blood Cancer 61(5):827\u2013832. https:\/\/doi.org\/10.1002\/pbc.24871","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"1787_CR37","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/blood-2014-03-560847","volume":"124","author":"D O'Connor","year":"2014","unstructured":"O\u2019Connor D, Bate J, Wade R et al (2014) Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood 124(7):1056\u20131061. https:\/\/doi.org\/10.1182\/blood-2014-03-560847","journal-title":"Blood"},{"issue":"2","key":"1787_CR38","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/annonc\/mdw557.PMID:28426102;PMCID:PMC5834143","volume":"28","author":"H Inaba","year":"2017","unstructured":"Inaba H, Pei D, Wolf J et al (2017) Infection-related complications during treatment for childhood acute lymphoblastic leukemia. Ann Oncol 28(2):386\u2013392. https:\/\/doi.org\/10.1093\/annonc\/mdw557.PMID:28426102;PMCID:PMC5834143","journal-title":"Ann Oncol"},{"issue":"26","key":"1787_CR39","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","volume":"115","author":"RC Harvey","year":"2010","unstructured":"Harvey RC, Mullighan CG, Chen IM et al (2010) Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 115(26):5312\u201321. https:\/\/doi.org\/10.1182\/blood-2009-09-245944","journal-title":"Blood"},{"issue":"1","key":"1787_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13063-022-06033-1","volume":"23","author":"N Das","year":"2022","unstructured":"Das N, Banavali S, Bakhshi S et al (2022) Protocol for ICiCLe-ALL-14 (InPOG-ALL-15\u201301): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India. Trials 23(1):102. https:\/\/doi.org\/10.1186\/s13063-022-06033-1","journal-title":"Trials"},{"issue":"12","key":"1787_CR41","doi-asserted-by":"publisher","first-page":"e27366","DOI":"10.1002\/pbc.27366","volume":"65","author":"M Parihar","year":"2018","unstructured":"Parihar M, Singh MK, Islam R et al (2018) A triple-probe FISH screening strategy for risk-stratified therapy of acute lymphoblastic leukaemia in low-resource settings. Pediatr Blood Cancer 65(12):e27366. https:\/\/doi.org\/10.1002\/pbc.27366","journal-title":"Pediatr Blood Cancer"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-024-01787-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-024-01787-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-024-01787-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T16:31:39Z","timestamp":1738686699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-024-01787-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1787"],"URL":"https:\/\/doi.org\/10.1007\/s12288-024-01787-x","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,18]]},"assertion":[{"value":"1 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}